Previous 10 | Next 10 |
WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and busines...
Minerva Neurosciences, Inc. (NERV) Q4 2020 Earnings Conference Call March 08, 2021, 08:30 AM ET Company Participants William Boni - VP, IR and Corporate Communications Remy Luthringer - Executive Chairman and Chief Executive Officer Geoff Race - Executive Vice President, Chief Financial Offic...
Image source: The Motley Fool. Minerva Neurosciences (NASDAQ: NERV) Q4 2020 Earnings Call Mar 08, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Minerva Neurosciences (NERV) Q4 2020 Earnings Call Transcript
Minerva Neurosciences (NERV): Q4 GAAP EPS of -$0.17 beats by $0.02.Cash, cash equivalents and restricted cash of ~$25.5MShares are up 9.79% PMPress Release For further details see: Minerva Neurosciences EPS beats by $0.02
Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021 Minerva’s royalty interest in seltorexant acquired by Royalty Pharma for an upfront payment of $60 million and up to $95 millio...
WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and busin...
Royalty Pharma is a unique entity in the healthcare ecosystem. The company is a royalty play as it acquires the rights to either late-stage products or commercially available entities. The goal is to capitalize on the long-term revenue generation of the product class before patent...
Gainers: [[PRTA]] +35.6%. [[CRBP]] +30.0%. [[GPRO]] +6.8%. [[VYNE]] +5.7%. [[LOTZ]] +3.6%.Losers: [[CRUS]] -7.5%. [[RMBS]] -6.3%. [[STRO]] -6.0%. [[ALTR]] -5.4%. [[NERV]] -5.1%. For further details see: PRTA, RMBS, NERV and GPRO among after-hours movers
Gainers: [[ADMS]] +13.2%. [[CTMX]] +5.6%. [[MSTR]] +4.9%. [[FARM]] +4.8%. [[NERV]] +4%.Losers: [[CATB]] -10.6%. [[PTVE]] -8%. [[MRVI]] -3.9%. [[ZI]] -3.8%. [[ICON]] -3.5%. For further details see: MSTR, ZI, ADMS and CATB among after-hours movers
NEW YORK and WALTHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up to $...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...